Navigation Links
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Date:8/5/2008

SHELTON, Conn., Aug. 5 /PRNewswire/-- Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be associated with clinical analgesic activity. In addition, CR845 infusion triggered a quantitative endocrine biomarker of peripheral kappa opioid receptor activation at the lowest dose tested.

The Phase Ia single-center clinical trial evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown to be safe at all doses investigated, with no reports of serious side effects or adverse central nervous system activity. Linear, dose-proportional increases in systemic exposure to CR845 were observed. Low doses of CR845 resulted in plasma levels at or above the plasma levels of drug expected to be associated with clinical analgesic efficacy.

The Company plans to advance its intravenous formulation of CR845 into Phase II trials later in 2008. Based on the demonstrated safety, tolerability, and bioactivity of this formulation in Phase I, Cara will continue to develop its oral formulation of CR845 for advancement into Phase I.

About CR845

CR845 was designed to be highly selective for the peripheral kappa opioid receptor, with a prolonged duration of action relative to Cara's first generation of peripheral kappa opioids. Animal studies indicate that CR845 is effective in reducing pain of inflammatory, neuropathic and visceral origin. The analgesic and anti-inflammatory effects of CR845 lasted for up to 18 hours after a single dose. CR845 was active after intravenous, subcutaneous, or oral administration. Preclinical studies also indicate that CR845 possesses anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing, or elicit signs of addiction in animal models. CR845 and related compounds are covered by a recently issued U.S. patent.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates within multiple classes of peripherally-acting analgesics. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen(TM) technology.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward-looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, ... growing market of deep learning solutions within the healthcare domain. Primarily ... as a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by ... it does not obey the rules Congress has directed the CBO to follow. The ... GOP reform would restore. Yet, it estimates a reduction in employer-based coverage due to ...
(Date:3/24/2017)... MI (PRWEB) , ... March 24, 2017 , ... ... assistance, financial planning, and related services to families and business owners across eastern ... aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH ...
(Date:3/24/2017)... ... 2017 , ... As the standards bearer of advanced cancer ... positions them as the go-to thought leader in all matters concerning oncology nursing. ... always-on, always-fresh news, views and advocacy engine, called ONS Voice. , The ONS ...
(Date:3/24/2017)... , ... March 24, 2017 , ... The law firm ... Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined the ... for the firm, will concentrate her practice in elder law, Medicaid planning and applications, ...
Breaking Medicine News(10 mins):